Cephalosporin Market Overview:

The Global Cephalosporin Marketwas valued at $77,764 million in 2016, and is estimated to reach $1,99,754 million by 2023, growing at a CAGR of 14.4% from 2017 to 2023. Cephalosporin is a bactericidal β-lactam antibiotic, which is used to treat bacterial infections such as pneumonia, skin infections, strep throat, staph infections, tonsillitis, bronchitis, otitis media, and gonorrhea. Increase in incidence of population suffering from pneumonia, tonsillitis, bronchitis, and gonorrhea drives the market growth. In addition, increase in R&D activities to develop highly efficient & safe drugs and upsurge in use of combination therapies boost the growth of the market. However, side effects associated with cephalosporin and development of drug-resistant bacterial strains impede the market growth.

Increase in the number of people suffering from infectious disease worldwide is the major factor that fuels the market growth. According to the 2016 estimates of WHO, nearly one million sexually transmitted infections (STIs) are acquired every day throughout the globe, accounting for more than 340 million new cases of sexually transmitted bacterial and protozoal infections in a year. In addition, a 2016 research article stated that urinary tract infections (UTI) are one of the most common bacterial infections, which affect nearly 150 million people per year globally. Thus, rise in prevalence of various bacterial diseases increase the customer base for cephalosporin, which in turn is anticipated to supplement the growth of the cephalosporin market.

Growth in Asia-Pacific region

Asia-Pacific is a potential market for cephalosporin drugs due to high population base, presence of unmet medical needs, and increase in disposable income of people. Asia-Pacific is densely populated, with India and China being the most populated countries. With a total population of more than 1.2 billion, India is one of the most promising markets for cephalosporin after China. Thus, the key players focus on expansion of their cephalosporin business in this region.

Advent of Combination Drugs

Use of combination drugs such as multiple antibacterials or antibacterials combined with an inhibitor may decrease the chances of evolution of antibiotic-resistant bacterial strains. Thus, increase in R&D activities has been witnessed for the development of combinations of cephalosporin that may be used against antibiotic-resistant bacteria. This is further expected to lead towards the growth of cephalosporin market.

The global cephalosporin market is segmented on the basis of generation, type, route of drug administration, application, and region. Based on generation, the market is divided into first-generation cephalosporin, second-generation cephalosporin, third-generation cephalosporin, fourth-generation cephalosporin, and fifth-generation cephalosporin. By type, it is bifurcated into branded and generics. Depending on route of drug administration, it is classified into injection and oral. The applications covered in the study include respiratory tract infection, skin infection, ear infection, urinary tract infection, sexually transmitted infection, and others. Geographically, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

8.2.3.1.1. U.S. cephalosporin market by generation
8.2.3.1.2. U.S. cephalosporin market by type
8.2.3.1.3. U.S. cephalosporin market by route of drug administration
8.2.3.1.4. U.S. cephalosporin market by application

Request for Table of Content

Globally, rise in incidence of pneumonia, tonsillitis, bronchitis, and gonorrhea constitutes a major proportion of health and economic burden. Therefore, advent of superior drugs is a necessary treatment option of these infections.

Upsurge in the population suffering from infections such as sexually transmitted infections boosts the market growth. Moreover, increased approvals of drugs and growth in awareness about various infections & antibiotic resistance propel the growth of the market Increase in use of combination therapies further leads to the growth of the market.

Asia-Pacific offers lucrative opportunities for the market growth due to rapid increase in population coupled with rise in incidence of infectious disease. Thus, emerging countries, such as China and India, possess high growth potential for the market.